Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in primary hypercholesterolemia without statin treatment
NL-OMON41636Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia and familial hypercholesterolemia (FH), sponsored by Sanofi. Started Jan 2014; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON41636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41636.